ERBB2 and breast cancer: Another weakness, in order to classify patients in a given risk group, is the fact that nearly 60% of patients had an unknown HER2 status, in consequence, a substantial number of patients, could not be evaluated regarding the TN phenotype, one of the major risk factors for hereditary breast cancer.